1.0Myanmar News Gazettehttps://myanmarnewsgazette.comadminhttps://myanmarnewsgazette.com/author/admin/rich600338<blockquote class="wp-embedded-content" data-secret="6olXuGkXJq"><a href="https://myanmarnewsgazette.com/uk-marketing-authorisations-for-iopidine-apraclonidine-fully-transferred-to-essential-pharma-as-change-in-uk-nice-guidelines-for-glaucoma-treatment-expected-to-lead-to-increase-in-patients/">UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need for product</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://myanmarnewsgazette.com/uk-marketing-authorisations-for-iopidine-apraclonidine-fully-transferred-to-essential-pharma-as-change-in-uk-nice-guidelines-for-glaucoma-treatment-expected-to-lead-to-increase-in-patients/embed/#?secret=6olXuGkXJq" width="600" height="338" title="“UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need for product” — Myanmar News Gazette" data-secret="6olXuGkXJq" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); </script> UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need for product Recent change in NICE guidelines indicating laser surgery as first line therapy for glaucoma is expected to increase need for IOPIDINE to control or prevent […]https://ci4.googleusercontent.com/proxy/Zd4_OA-HRFe4Adegu2ZR2OXyOHUTmnRtyaiVB5C_3a-PlzzHjER93m7BGUzj4HfpdZwQjSOXLavlrFz1FYak-nhN5Glbd7pa53la_pNuCdiI3mQIhi5fLr2NH-6pJmUPahqg6xEdwZA=s0-d-e1-ft#https://www.globenewswire.com/newsroom/ti?nf=MTAwMDc3MjQ0NSM0MDE0NDQ1NDcjNzAwMDEzNjAx